A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2017
At a glance
- Drugs CGF 166 (Primary)
- Indications Hearing loss
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 14 Mar 2017 Planned End Date changed from 1 Aug 2017 to 12 Jun 2019.
- 14 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 12 Jun 2019.
- 05 Aug 2016 According to a GenVec media release, enrollment is underway in the fourth cohort.